Liver Fatty Acid Binding Protein (FABP1) Affects Cytochrome P450 2C9 (CYP2C9)-Mediated Metabolism in Human Liver Models
- 1University of Washington
Abstract
Metabolic clearance of drugs is often systematically over- or underpredicted from human liver microsomes (HLM). We hypothesized that lack of consideration of interactions of cytosolic liver fatty acid binding protein (FABP1) with drugs and cytochrome P450s (CYPs) explains the off-prediction. We used two CYP2C9 probe substrates, diclofenac and tolbutamide, to test this hypothesis. We found that presence of FABP1 alters the kinetics of metabolite formation in HLM. The model that best fit the kinetic data included FABP1-CYP2C9 protein-protein interactions. Statistical modeling of proteomic expression and drug hydroxylation across a panel of 61 human liver S9 fractions (HLS9) showed that CYP2C9 and FABP1 expression together best predicted probe substrate hydroxylation. Incorporation of FABP1 expression and protein-protein interactions into novel physiologically based liver models significantly improved the quantitative accuracy of in vivo hepatic clearance prediction. Together, our data demonstrate the importance of taking FABP1 into consideration for CYP2C9-mediated metabolism.
Related
- Characterization of Cytochrome P450-Mediated Metabolism of Δ8-tetrahydrocannabinol in vitro
- Cell-surface expression of the RNA binding protein U5 snRNP200 on acute myeloid leukemia and other tumor cells is independent of FcγR-mediated interactions
- Decreased expression of Acsm2 disrupts energy metabolism and affects cell death in acute kidney injury
- Aromaticity at spike position 456 affects functional immunogenicity of SARS-CoV-2 Omicron variant receptor-binding domain.
- Tissue-specific variability in protein expression of cytochrome P450 and glutathione S-transferase isoenzymes in non-small cell lung carcinoma.
BibTeX
@misc{wen2026liver,
title = {{Liver Fatty Acid Binding Protein (FABP1) Affects Cytochrome P450 2C9 (CYP2C9)-Mediated Metabolism in Human Liver Models}},
author = {Y. W. Wen and E. Friedman and A. Zelter and K. C. Yabut and A. Nath and M. J. MacCoss and N. Isoherranen},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.12.758325},
url = {https://www.biorxiv.org/content/10.64898/2026.10.12.758325v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - Liver Fatty Acid Binding Protein (FABP1) Affects Cytochrome P450 2C9 (CYP2C9)-Mediated Metabolism in Human Liver Models
AU - Y. W. Wen
AU - E. Friedman
AU - A. Zelter
AU - K. C. Yabut
AU - A. Nath
AU - M. J. MacCoss
AU - N. Isoherranen
PY - 2026
DA - 2026/10/12
PB - bioRxiv
DO - 10.64898/2026.10.12.758325
UR - https://www.biorxiv.org/content/10.64898/2026.10.12.758325v1
AB - Metabolic clearance of drugs is often systematically over- or underpredicted from human liver microsomes (HLM). We hypothesized that lack of consideration of interactions of cytosolic liver fatty acid binding protein (FABP1) with drugs and cytochrome P450s (CYPs) explains the off-prediction. We used two CYP2C9 probe substrates, diclofenac and tolbutamide, to test this hypothesis. We found that presence of FABP1 alters the kinetics of metabolite formation in HLM. The model that best fit the kinetic data included FABP1-CYP2C9 protein-protein interactions. Statistical modeling of proteomic expression and drug hydroxylation across a panel of 61 human liver S9 fractions (HLS9) showed that CYP2C9 and FABP1 expression together best predicted probe substrate hydroxylation. Incorporation of FABP1 expression and protein-protein interactions into novel physiologically based liver models significantly improved the quantitative accuracy of in vivo hepatic clearance prediction. Together, our data demonstrate the importance of taking FABP1 into consideration for CYP2C9-mediated metabolism.
ER -